Nucala becomes first med to significantly reduce HES flares
Patients had 50% fewer flares on the drug compared to placebo.
13th November 2019
Latest news
Parkinsons UK granted £200,000 for Virtual Biotech
The money will go towards a potential new therapy and project, seeking to discover new ways that may prevent brain cell death.
12th November 2019
Tremfya hits endpoints in psoriatic arthritis study
24-week data from the clinical trial showed at least a 20% improvement in disease signs and symptoms compared to placebo.
12th November 2019
Kisqali leads latest SMC decisions
The committee accepted breast cancer and kidney cancer treatments, but rejected one non-small cell lung cancer (NSCLC) therapy.
12th November 2019
Roche's Gazyva shows promise in lupus nephritis
The drug met its primary endpoint, demonstrating superiority compared to placebo with standard of care.
12th November 2019
Tickets now available for the 2019 Medical & Scientific Excellence Awards ceremony
This year’s event will be taking place at The Hilton Hotel in Reading on the 5th December.
12th November 2019
Roche’s risdiplam hits targets in SMA trial
The results are from the largest placebo-controlled study ever undertaken in type I or III SMA patients.
11th November 2019
Horizon divests animal models business to Envigo
The agreement is expected to be completed within 30-45 days.
11th November 2019
Bavencio falls at late-stage hurdle
Topline results showed that the drug didn't meet the primary endpoints of superior overall survival, compared with standard of care.
11th November 2019
NICE U-turn for Epidyolex in epilepsy
Despite the good news, there is still “disappointment surrounding the restrictions on prescribing cannabis-based drugs in the UK."
11th November 2019
Roxadustat hits efficacy, CV targets in CKD-related anaemia
The data marks an important milestone for CKD-related anaemia patients, as it is the "first innovation of its kind for this market in many years.”
11th November 2019
ObsEva ditches IVF trial after disappointing late-stage results
The treatment fell short of its primary endpoint of increase in ongoing pregnancy rate at 10 weeks.
8th November 2019
MSD recruits Promega for Keytuda companion diagnostic
Keytruda is predicted to be the best-selling drug by annual revenue in 2023.
8th November 2019
J&J submits EMA applications for Ebola vaccine
The MAAs are supported by data from Phase I, II and III clinical studies.
8th November 2019
Owlstone, Thermo Fisher team up for early disease detection
If successful, Thermo's mass analyser will become a standard part of Owlstone Medical’s biomarker discovery process.
8th November 2019
